Drug resistance of Mycobacterium tuberculosis in the Sunamganj District of Bangladesh
Drug resistance of Mycobacterium tuberculosis in the Sunamganj District of Bangladesh
复制标题
DOI：
10.1080/00365540600951242
复制
发表时间：
2007-01-01
影响因子：
--
通讯作者：
Mannsaker, Turid
中科院分区：
文献类型：
--
作者：
Storla, Dag Gundersen;Rahim, Zeaur;Mannsaker, Turid
耐药结核病的传播威胁着结核病控制方案，所有国家都需要监测抗结核耐药性的模式和趋势。这些数据评估控制程序的质量，并有助于预测未来的抗药性趋势。它还将有助于建立结核病治疗指南。目前这项研究的目的是描述孟加拉国Sunamganj区耐药结核分枝杆菌的比率。细菌分离株来自2003年11月至2004年12月参加国家结核病规划的涂阳患者。在奥斯陆挪威公共卫生研究所(NIPH)的国家分枝杆菌参考实验室，共检测了95株分离株对链霉素(SM)、异烟肼(INH)、利福平(RMP)和乙胺丁醇(EMB)的敏感性。新发病例对任何药物的总耐药率为31%。对SM的耐药率为18%，异烟肼为23%，RMP为2%，EMB为10%，多药耐药(MDR)为2%。Sunamganj的国家结核病规划(NTP)仍然有效，尽管对异烟肼的高耐药性令人震惊。在异烟肼耐药水平高的地区，治疗失败的风险增加，而且在治疗期间，高比例的异烟肼耐药病例可能会对RMP产生耐药性。
Spread of drug-resistant tuberculosis (TB) threatens TB-control programmes, and all countries need to monitor the patterns and trends of anti-TB drug resistance. Such data assess the quality of control programmes and help forecast future trends of drug resistance. It will also help to establish guidelines for TB therapy. The aim of the current study was to describe the rate of drug-resistant Mycobacterium tuberculosis in the Sunamganj District of Bangladesh. Bacterial isolates were collected from sputum smear positive (ss +) patients who attended the National TB Programme from November 2003 to December 2004. A total of 95 isolates was tested for susceptibility to streptomycin (SM), isoniazid (INH), rifampicin (RMP) and ethambutol (EMB) at the National Reference Laboratory for Mycobacteria at the Norwegian Institute of Public Health (NIPH), Oslo. The total resistance among new cases to any drug was 31%. For SM it was 18%, INH 23%, RMP 2%, EMB 10% and 2% were multidrug-resistant (MDR). The National Tuberculosis Programme (NTP) in Sunamganj is still effective, although the high resistance to INH is alarming. An increased risk of treatment failure has been demonstrated in areas with high levels of INH resistance, and a high proportion of INH resistant cases may develop resistance to RMP during treatment.